Novo Nordisk confirms counterfeit Ozempic pens found at a US pharmacy
Counterfeit Ozempic pens turned up at a US retail pharmacy for the first time, putting fake product inside the supply chain patients normally trust.
In June 2023, Novo Nordisk confirmed that counterfeit Ozempic pens had been found at a US retail pharmacy — the first time fake versions of the drug were detected inside the legitimate US supply chain [1]. The company warned patients to check the lot and serial numbers on their pens [1].
The detail that matters most is location. Counterfeit versions of popular GLP-1 drugs had previously been associated with online sellers and other channels outside pharmacy oversight, where a buyer has no manufacturer or licensed pharmacy standing behind the product. This case, confirmed by Novo Nordisk, involved a retail pharmacy, a setting where patients generally assume the product on the shelf is genuine [1].
Ozempic is the brand name for semaglutide, a GLP-1 medicine that Novo Nordisk sells [1]. The counterfeit finding was reported for Ozempic, and the company's warning was directed at patients using the drug [1].
Several basic facts about the case have not been reported. It has not been disclosed how many counterfeit pens were found, which pharmacy or state they were found in, whether the pens contained semaglutide or another substance, or whether anyone was injured [1]. Whether the fake pens came from a single batch or several also has not been made public [1].
Novo Nordisk's guidance centered on two sets of markings [1]. A lot number identifies the batch a pen came from, and a serial number identifies an individual pen. The company pointed patients to those numbers as a way to check a pen against its own records [1]. Checking numbers is a different exercise from judging a box by its appearance, since counterfeits are typically designed to resemble the real packaging.
Why it matters for patients
For anyone taking semaglutide, the practical effect of this finding is narrower than a headline suggests, but it is real. The confidence a patient places in a pharmacy purchase rests on the idea that the path from the factory to the counter is closed to outside product. A confirmed counterfeit pen at retail is the first such sign reported inside that path [1].
What a counterfeit pen contains, and whether it delivers the labeled dose of semaglutide, has not been disclosed [1]. For someone using Ozempic to manage type 2 diabetes, a pen that does not contain what its label says could mean a dose that does not match what a prescription calls for; no such case is described in this finding [1].
The warning from Novo Nordisk was specific: check lot and serial numbers [1]. What patients were told to do if a number did not match was not spelled out in the company's warning as reported [1].
It also is not known whether the counterfeit pens were limited to one pharmacy or reflect a wider distribution problem [1].
What happens next
No recall tied to a specific lot, no arrest, and no new regulatory action connected to this finding has been reported [1]. It has not been disclosed how the counterfeit pens entered the pharmacy's inventory, or whether investigators identified a source [1]. The one concrete step described is Novo Nordisk's instruction to patients to verify the lot and serial numbers on their pens [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.